I'm really excited that adaptive trial design is finally getting noticed instead of being a niche topic that only elite cancer trialists get excited about.

Have you seen the new program from ARPA-H?


They hope to spur development of adaptive biomarkers for evolving metastatic cancers with the kind of trial design that ought to be the gold standard for precision medicine.

Expand full comment

Really enjoyed reading + love the clinical context of the ctDNA seq advancement.

Expand full comment